Physician profile
Daniel Alexcander Serrano
NPI 1467034355
$710.42
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $500 · 2022: $91.50 · 2023: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $118.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $130.60 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $118.71 | 2023 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $101.23 | 2021 | |
| Glaxosmithkline, LLC. | $91.50 | 2022 | |
| Biogen, INC. | $40.88 | 2021 | |
| Neurelis, INC. | $34.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $33.52 | 2021 | |
| Emd Serono, INC. | $32.48 | 2021 | |
| Avanir Pharmaceuticals, INC. | $23.52 | 2021 | |
| Amneal Pharmaceuticals LLC | $20.32 | 2021 | |
| Adamas Pharmaceuticals, INC. | $18.85 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.49 | 2021 | |
| Lilly USA, LLC | $15.64 | 2021 | |
| Scilex Pharmaceuticals INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.